Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β
Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β
Extracellular plaques of amyloid-β and intraneuronal neurofibrillary tangles made from tau are the histopathological signatures of Alzheimer's disease. Plaques comprise amyloid-β fibrils that assemble from monomeric and oligomeric intermediates, and are prognostic indicators of Alzheimer's disease. Despite the importance of plaques to Alzheimer's disease, oligomers are considered to be the principal toxic forms of amyloid-β. Interestingly, many adverse responses to amyloid-β, such as cytotoxicity, microtubule loss, impaired memory and learning, and neuritic degeneration, are greatly amplified by tau expression. Amino-terminally truncated, pyroglutamylated (pE) forms of amyloid-β are strongly associated with Alzheimer's disease, are more toxic than amyloid-β, residues 1-42 (Aβ(1-42)) and Aβ(1-40), and have been proposed as initiators of Alzheimer's disease pathogenesis. Here we report a mechanism by which pE-Aβ may trigger Alzheimer's disease. Aβ(3(pE)-42) co-oligomerizes with excess Aβ(1-42) to form metastable low-n oligomers (LNOs) that are structurally distinct and far more cytotoxic to cultured neurons than comparable LNOs made from Aβ(1-42) alone. Tau is required for cytotoxicity, and LNOs comprising 5% Aβ(3(pE)-42) plus 95% Aβ(1-42) (5% pE-Aβ) seed new cytotoxic LNOs through multiple serial dilutions into Aβ(1-42) monomers in the absence of additional Aβ(3(pE)-42). LNOs isolated from human Alzheimer's disease brain contained Aβ(3(pE)-42), and enhanced Aβ(3(pE)-42) formation in mice triggered neuron loss and gliosis at 3 months, but not in a tau-null background. We conclude that Aβ(3(pE)-42) confers tau-dependent neuronal death and causes template-induced misfolding of Aβ(1-42) into structurally distinct LNOs that propagate by a prion-like mechanism. Our results raise the possibility that Aβ(3(pE)-42) acts similarly at a primary step in Alzheimer's disease pathogenesis.
- Leibniz Association Germany
- University of California, Irvine United States
- University of Virginia United States
- Leibniz Institute for Neurobiology Germany
- UNIVERSITY OF CALIFORNIA IRVINE
Amyloid, drug effects [Amyloid], Prions, toxicity [Amyloid], metabolism [Amyloid beta-Peptides], Glutamic Acid, Mice, Transgenic, tau Proteins, deficiency [tau Proteins], Article, Mice, toxicity [Prions], Alzheimer Disease, chemistry [Amyloid], genetics [Amyloid beta-Peptides], metabolism [Peptide Fragments], Animals, Humans, metabolism [Mutant Proteins], metabolism [Amyloid], Amyloid beta-Peptides, metabolism [Glutamic Acid], chemistry [Glutamic Acid], toxicity [Peptide Fragments], chemistry [Prions], toxicity [Mutant Proteins], amyloid beta-protein (1-42), genetics [Peptide Fragments], metabolism [tau Proteins], Peptide Fragments, toxicity [Amyloid beta-Peptides], genetics [tau Proteins], Disease Models, Animal, chemistry [Mutant Proteins], chemistry [Peptide Fragments], metabolism [Prions], genetics [Mutant Proteins], Mutant Proteins, chemistry [Amyloid beta-Peptides], metabolism [Alzheimer Disease], ddc: ddc:500
Amyloid, drug effects [Amyloid], Prions, toxicity [Amyloid], metabolism [Amyloid beta-Peptides], Glutamic Acid, Mice, Transgenic, tau Proteins, deficiency [tau Proteins], Article, Mice, toxicity [Prions], Alzheimer Disease, chemistry [Amyloid], genetics [Amyloid beta-Peptides], metabolism [Peptide Fragments], Animals, Humans, metabolism [Mutant Proteins], metabolism [Amyloid], Amyloid beta-Peptides, metabolism [Glutamic Acid], chemistry [Glutamic Acid], toxicity [Peptide Fragments], chemistry [Prions], toxicity [Mutant Proteins], amyloid beta-protein (1-42), genetics [Peptide Fragments], metabolism [tau Proteins], Peptide Fragments, toxicity [Amyloid beta-Peptides], genetics [tau Proteins], Disease Models, Animal, chemistry [Mutant Proteins], chemistry [Peptide Fragments], metabolism [Prions], genetics [Mutant Proteins], Mutant Proteins, chemistry [Amyloid beta-Peptides], metabolism [Alzheimer Disease], ddc: ddc:500
26 Research products, page 1 of 3
- 2017IsRelatedTo
- 2017IsRelatedTo
- 2017IsRelatedTo
- 2017IsRelatedTo
- 2017IsRelatedTo
- 2017IsRelatedTo
- 2017IsRelatedTo
chevron_left - 1
- 2
- 3
chevron_right
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).398 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 1% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 0.1%
